Literature DB >> 22977547

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines.

Satoshi Tabuchi1, Soji Ozawa, Kazuo Koyanagi, Naoyuki Shigematsu, Atsushi Kubo, Masakazu Ueda, Yuko Kitagawa, Masaki Kitajima.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is more sensitive to radiation and chemotherapy than other cancers of the digestive system, and combined modality therapy may represent a promising treatment method. The radiation-sensitizing effect of docetaxel on ESCC cell lines was investigated. A colony formation assay was performed in which ESCC cell lines (TE2, TE3) and A431 were exposed to docetaxel (from 1.0×10(-11) to 10(-7) M) for 3 h to determine the concentration of docetaxel that was not able to kill individual cells (i.e., the non-cytocidal concentration). Individual cell lines were then exposed to the non-cytocidal concentration of docetaxel prior to, during, and after irradiation to determine whether the timing of docetaxel administration affected cell survival. In addition, flow-cytometry was performed, and the cell cycle was examined prior to and after docetaxel exposure to assess the mechanism of docetaxel as a radiation sensitizer. Docetaxel exhibited a concentration-dependent cytocidal effect, with a different IC(50) for each cell type. Almost no cytocidal effect was observed at the following docetaxel concentrations: A431, ≤1.0×10(-10) M; TE-2 and TE-3, ≤1.0×10(-9) M. Concurrent treatment with docetaxel and radiation tended to decrease cell survival in all the cell lines compared with docetaxel or radiation alone. Cell survival was lowest when the cells were treated using X-ray irradiation after docetaxel exposure (p<0.05). Flow cytometry revealed that in all three cell lines, docetaxel exposure increased the G2/M cell fraction with a higher increase in the cell line that exhibited the highest radiosensitivity. This study demonstrated that the administration of docetaxel at a non-cytocidal concentration prior to radiotherapy produced a synergistic cell-killing effect in SCC cell lines.

Entities:  

Year:  2011        PMID: 22977547      PMCID: PMC3440770          DOI: 10.3892/etm.2011.263

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

1.  Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ).

Authors:  O Pradier; M Rave-Fränk; J Lehmann; E Lücke; O Boghun; C F Hess; H Schmidberger
Journal:  Int J Cancer       Date:  2001-03-15       Impact factor: 7.396

2.  Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study.

Authors:  L R Coia; B D Minsky; B A Berkey; M J John; D Haller; J Landry; T M Pisansky; C G Willett; J P Hoffman; J B Owen; G E Hanks
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.

Authors:  K A Mason; K Kishi; N Hunter; L Buchmiller; T Akimoto; R Komaki; L Milas
Journal:  Clin Cancer Res       Date:  1999-12       Impact factor: 12.531

4.  Docetaxel: an active drug for squamous cell carcinoma of the head and neck.

Authors:  A I Dreyfuss; J R Clark; C M Norris; R M Rossi; J W Lucarini; P M Busse; M D Poulin; L Thornhill; R Costello; M R Posner
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

5.  Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.

Authors:  M I Koukourakis; C Kourousis; M Kamilaki; S Koukouraki; A Giatromanolaki; S Kakolyris; A Kotsakis; N Androulakis; N Bahlitzanakis; V Georgoulias
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162

Review 6.  Docetaxel and radiation as combined-modality therapy.

Authors:  Edward S Kim; Fadlo R Khuri
Journal:  Oncology (Williston Park)       Date:  2002-06       Impact factor: 2.990

7.  Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck.

Authors:  Masato Fujii; Mamoru Tsukuda; Bunsuke Satake; Akira Kubota; Akinori Kida; Naoyuki Kohno; Kenji Okami; Yukio Inuyama
Journal:  Int J Clin Oncol       Date:  2004-04       Impact factor: 3.402

8.  Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

Authors:  Nobutoshi Ando; Toshifumi Iizuka; Hiroko Ide; Kaoru Ishida; Masayuki Shinoda; Tadashi Nishimaki; Wataru Takiyama; Hiroshi Watanabe; Kaichi Isono; Norio Aoyama; Hiroyasu Makuuchi; Otsuo Tanaka; Hideaki Yamana; Shunji Ikeuchi; Toshiyuki Kabuto; Kagami Nagai; Yutaka Shimada; Yoshihide Kinjo; Haruhiko Fukuda
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

9.  Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

Authors:  G Catimel; J Verweij; V Mattijssen; A Hanauske; M Piccart; J Wanders; H Franklin; N Le Bail; M Clavel; S B Kaye
Journal:  Ann Oncol       Date:  1994-07       Impact factor: 32.976

10.  Docetaxel enhances tumor radioresponse in vivo.

Authors:  K A Mason; N R Hunter; M Milas; J L Abbruzzese; L Milas
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

View more
  2 in total

1.  The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis.

Authors:  Liang Jin; Ning Shi; Shiye Ruan; Baohua Hou; Yiping Zou; Xiongfeng Zou; Haosheng Jin; Zhixiang Jian
Journal:  Radiat Oncol       Date:  2020-04-09       Impact factor: 3.481

2.  MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2.

Authors:  Ying Shao; Peng Li; Sheng-Tao Zhu; Ji-Ping Yue; Xiao-Jun Ji; Dan Ma; Li Wang; Yong-Jun Wang; Ye Zong; Yong-Dong Wu; Shu-Tian Zhang
Journal:  Oncotarget       Date:  2016-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.